Patient demographics and management by care provider
| Primary care (n=878) | Secondary care (n=2326) | P value | ||
| Age at point prevalence | (mean) | 59.3 (47.5–72.0) | 52.0 (37.8–66.1) | <0.001 |
| Sex | Male | 425 (48.4%) | 1130 (48.6%) | 0.935 |
| Ethnicity | British/white | 696 (79.3%) | 2293 (98.6%) | NA (missing data) |
| Mixed | 3 (0.3%) | 6 (0.3%) | ||
| Asian | 3 (0.3%) | 8 (0.4%) | ||
| Not recorded | 176 (20.1%) | 19 (0.8%) | ||
| Smoking history | Never | 371 (42.3%) | 945 (40.6.0%) | NA (missing data) |
| Current | 59 (6.7%) | 248 (10.6%) | ||
| Ex | 231 (26.3%) | 835 (35.9%) | ||
| Not recorded | 217 (24.7%) | 298 (12.8%) | ||
| Income decile | (median) | 6.0 (5.0–7.0) | 6.0 (4.0–7.0) | 0.422 |
| Disease | UC | 613 (69.8%) | 1355 (58.3%) | <0.001 |
| CD | 226 (25.7%) | 865 (37.2%) | ||
| IBDU | 39 (4.4%) | 106 (4.5%) | ||
| Age at diagnosis | (years) | 38.0 (35.4–48.2) | 38.8 (35.6–51.8) | 0.752 |
| Disease duration | (years) | 21.1 (18.3–29.3) | 13.2 (9.5–18.6) | <0.001 |
| Montreal: age | A1 | 63 (7.2%) | 154 (6.6%) | 0.126 |
| A2 | 443 (50.4%) | 1159 (49.8%) | ||
| A3 | 336 (38.2%) | 951 (40.9%) | ||
| Not recorded | 36 (4.1%) | 62 (2.7%) | ||
| Montreal: location (CD only) | L1 | 60 (26.5%) | 383 (44.3%) | NA (missing data) |
| L2 | 58 (24.8%) | 240 (27.7%) | ||
| L3 | 18 (7.9%) | 232 (26.9%) | ||
| L4 | 2 (0.9%) | 4 (0.5%) | ||
| Not recorded | 88 (38.9%) | 6 (0.6%) | ||
| Montreal: behaviour (CD only) | B1 | 47 (20.7%) | 533 (61.6%) | NA (missing data) |
| B2 | 9 (3.9%) | 219 (25.2%) | ||
| B3 | 4 (1.7%) | 87 (10.0%) | ||
| Not recorded | 166 (73.4%) | 26 (3.0%) | ||
| Montreal: extent (UC only) | E1 | 160 (26.1%) | 371 (27.4%) | NA (missing data) |
| E2 | 107 (17.4%) | 540 (39.9%) | ||
| E3 | 167 (27.2%) | 438 (32.3%) | ||
| Not recorded | 218 (35.5%) | 6 (0.4%) | ||
| CD treatment | Immunomodulator (ever) | 13 (5.7%) | 535 (61.9%) | <0.001 |
| Biological (ever) | 2 (0.8%) | 307 (35.5%) | ||
| Bowel resection (any) | 82 (36.3%) | 299 (34.6%) | ||
| UC/IBDU treatment | Immunomodulator (ever) | 45 (7.3%) | 475 (35.1%) | <0.001 |
| Biological (ever) | 8 (1.2%) | 176 (12.9%) | ||
| Subtotal colectomy | 55 (8.4%) | 103 (7.0%) | ||
| Proctocolectomy | 86 (13.2%) | 23 (1.6%) | ||
| Eligible for surveillance (meet NICE criteria) | CD | 38 (16.8% of CD) | 222 (25.7% of CD) | <0.001 |
| UC/IBDU | 167 (25.6% of UC/IBDU) | 497 (34.1% of UC/IBDU) | ||
| Total eligible | 205 (23.3% of primary care IBD) | 719 (30.9% of secondary care IBD) |
Patients were considered as managed in secondary care if they had attended a consultant or nurse specialist IBD clinic or surgical outpatient appointment in the last 3 years, with ongoing follow-up planned and not expressly discharged by their clinician. Eligibility for surveillance based on NICE criteria is (1) disease duration greater than 10 years and (2) disease involving more than 50% or two segments of the colon. Patients with unknown Montreal L or E phenotype, or had undergone a total colectomy were not included.
CD, Crohn's disease; IBDU, inflammatory bowel disease unclassified; N/A, not applicable; NICE, National Institute for Health and Care Excellence; UC, ulcerative colitis.